I am not focused on today's price movement of the stock but the pattern from the end of 2017.
J&J said it would appeal the judge's decision. The judgment was less than Wall Street was expecting. The stock rose after hours.
Here's how to empower the next generation of women going into STEM.
Here's how a project--such as reinventing the lab coat--can empower the minds of tomorrow.
The biopharmaceutical company reports positive Phase 3 trial results for its cholesterol-lowering therapy inclisiran.
Jim Cramer breaks down Amgen's deal to buy Otezla's rights from Celgene.
Equality in the workplace matters.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
Recent speculation that the biotech giant would buy Alexion had boosted ALXN's shares. But Amgen just agreed to lay out $13.4 billion for Celgene's psoriasis drug.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.